[go: up one dir, main page]

SV2011003912A - Moduladores de aril metil benzoquinazolinona alostericos positivos del receptor m1 - Google Patents

Moduladores de aril metil benzoquinazolinona alostericos positivos del receptor m1

Info

Publication number
SV2011003912A
SV2011003912A SV2011003912A SV2011003912A SV2011003912A SV 2011003912 A SV2011003912 A SV 2011003912A SV 2011003912 A SV2011003912 A SV 2011003912A SV 2011003912 A SV2011003912 A SV 2011003912A SV 2011003912 A SV2011003912 A SV 2011003912A
Authority
SV
El Salvador
Prior art keywords
receiver
pharmaceutically acceptable
aril
acceptable salt
positive
Prior art date
Application number
SV2011003912A
Other languages
English (en)
Inventor
Scott D Kuduk
Marco Christina Ng Di
Douglas C Beshore
Thomas J Greshock
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of SV2011003912A publication Critical patent/SV2011003912A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/19—Acids containing three or more carbon atoms
    • C07C53/21—Acids containing three or more carbon atoms containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

NUEVOS COMPUESTOS DE ARIL METIL BENZOQUINAZOLINONA DE LA FÓRMULA GENÉRICA (I): (VER FORMULA); O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE LOS MISMOS, QUE ES ÚTIL COMO UN MODULADOR ALOSTÉRICO POSITIVO DEL RECEPTOR M1. EL INVENTO SE REFIERE ADICIONALMENTE A MÉTODOS PARA TRATAR UN PACIENTE (PREFERIBLEMENTE UN SER HUMANO) PARA ENFERMEDADES O TRASTORNOS EN LOS QUE EL RECEPTOR ML ESTÁ IMPLICADO, TALES COMO ENFERMEDAD DE ALZHEIMER, DETERIORO COGNITIVO, ESQUIZOFRENIA, TRASTORNOS POR DOLOR Y TRASTORNOS DEL SUEÑO, ADMINISTRANDO AL PACIENTE UNA CANTIDAD TERAPÉUTICAMENTE EFICAZ DE UN COMPUESTO DE FÓRMULA GENERAL (I) O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO. EL INVENTO TAMBIÉN SE REFIERE A COMPOSICIONES FARMACÉUTICAS QUE INCLUYEN UNA CANTIDAD EFICAZ DE UN COMPUESTO DE FÓRMULA (I), O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO, Y UN VEHÍCULO FARMACÉUTICAMENTE ACEPTABLE, Y EL USO DE LOS COMPUESTOS Y COMPOSICIONES FARMACÉUTICAS DEL INVENTO EN EL TRATAMIENTO DE DICHAS ENFERMEDADES
SV2011003912A 2008-11-20 2011-05-20 Moduladores de aril metil benzoquinazolinona alostericos positivos del receptor m1 SV2011003912A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19974008P 2008-11-20 2008-11-20

Publications (1)

Publication Number Publication Date
SV2011003912A true SV2011003912A (es) 2011-10-13

Family

ID=41565956

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2011003912A SV2011003912A (es) 2008-11-20 2011-05-20 Moduladores de aril metil benzoquinazolinona alostericos positivos del receptor m1

Country Status (36)

Country Link
US (4) US8557832B2 (es)
EP (1) EP2358686B1 (es)
JP (1) JP5102397B2 (es)
KR (1) KR101305590B1 (es)
CN (1) CN102292323B (es)
BR (1) BRPI0921924A2 (es)
CA (1) CA2743562C (es)
CO (1) CO6361928A2 (es)
CR (1) CR20110268A (es)
CY (1) CY1113665T1 (es)
DK (1) DK2358686T3 (es)
DO (1) DOP2011000135A (es)
EA (1) EA019098B1 (es)
EC (1) ECSP11011066A (es)
ES (1) ES2393694T3 (es)
GE (1) GEP20156348B (es)
GT (1) GT201100127A (es)
HN (1) HN2011001358A (es)
HR (1) HRP20120992T1 (es)
IL (1) IL212573A (es)
MA (1) MA32898B1 (es)
MX (1) MX2011005284A (es)
MY (1) MY162502A (es)
NI (1) NI201100100A (es)
NZ (1) NZ592961A (es)
PE (1) PE20120031A1 (es)
PL (1) PL2358686T3 (es)
PT (1) PT2358686E (es)
RS (1) RS52528B (es)
SG (1) SG171769A1 (es)
SI (1) SI2358686T1 (es)
SV (1) SV2011003912A (es)
TN (1) TN2011000209A1 (es)
UA (1) UA100459C2 (es)
WO (1) WO2010059773A1 (es)
ZA (1) ZA201103612B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20150572T1 (en) * 2009-08-31 2015-07-03 Merck Sharp & Dohme Corp. Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
US8895580B2 (en) 2009-10-21 2014-11-25 Merck Sharp & Dohme Corp. Quinolinone-pyrazolone M1 receptor positive allosteric modulators
EP2512245B1 (en) * 2009-12-14 2014-07-23 Merck Sharp & Dohme Corp. Pyridoquinazolinone m1 receptor positive allosteric modulators
AU2010340142B2 (en) 2009-12-17 2014-05-08 Merck Sharp & Dohme Corp. Quinoline amide M1 receptor positive allosteric modulators
US8383638B2 (en) * 2009-12-21 2013-02-26 Merck Sharp & Dohme Aminobenzoquinazolinone M1 receptor positive allosteric modulators
WO2011159553A1 (en) * 2010-06-15 2011-12-22 Merck Sharp & Dohme Corp. Heterocyclic fused phenanthrolinone m1 receptor positive allosteric modulators
WO2012003147A1 (en) 2010-07-01 2012-01-05 Merck Sharp & Dohme Corp. Isoindolone m1 receptor positive allosteric modulators
WO2012047702A1 (en) * 2010-10-04 2012-04-12 Merck Sharp & Dohme Corp. Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators
WO2012158473A1 (en) * 2011-05-17 2012-11-22 Merck Sharp & Dohme Corp. N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators
KR20140051403A (ko) 2011-08-12 2014-04-30 바스프 에스이 안트라닐아미드 화합물 및 살충제로서의 그의 용도
AR088148A1 (es) 2011-08-12 2014-05-14 Basf Se Compuestos de antranilamida y sus usos como plaguicidas
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
US9233911B2 (en) 2012-01-10 2016-01-12 Council Of Scientific & Industrial Research Cu-mediated annulation for the production of 1-amino-2-naphthalenecarboxylic acid derivatives
JP6211509B2 (ja) 2012-03-02 2017-10-11 武田薬品工業株式会社 複素環化合物およびその用途
US9777005B2 (en) 2012-11-19 2017-10-03 Takeda Pharmaceutical Company Limited Bicyclic heterocyclic compound containing a substituted pyrrole ring
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
US9975844B2 (en) 2014-04-17 2018-05-22 Sumitomo Chemical Company, Limited Method for producing nitro compound
CA2978214A1 (en) * 2015-03-06 2016-09-15 Chase Pharmaceuticals Corporation Peripheral-anticholinergic muscarinic agonist combination
MX2017016875A (es) 2015-06-26 2018-04-24 Takeda Pharmaceuticals Co Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores de receptor muscarinico colinergico m1.
US20180250270A1 (en) 2015-09-11 2018-09-06 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
US20180273507A1 (en) * 2015-09-30 2018-09-27 Merck Sharp & Dohme Corp. Crystal forms of a m1 receptor positive allosteric modulator
US10308633B2 (en) 2015-09-30 2019-06-04 Merck Sharp & Dohme Corp. Process for making M1 receptor positive allosteric modulators
WO2017069173A1 (ja) * 2015-10-20 2017-04-27 武田薬品工業株式会社 複素環化合物
PE20190472A1 (es) 2016-04-15 2019-04-04 Abbvie Inc Inhibidores de bromodominios
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2018069841A1 (en) 2016-10-14 2018-04-19 Pi Industries Ltd 4-substituted phenylamine derivatives and their use to protect crops by fighting undesired phytopathogenic micoorganisms
JP7139323B2 (ja) 2016-11-01 2022-09-20 エフ．ホフマン－ラ ロシュ アーゲー Ｃｎｓ関連疾患を処置するための１，３－ジヒドロ－１，４－ベンゾジアゼピン－２－チオン
EP3627152A4 (en) 2017-05-19 2021-02-24 Takeda Pharmaceutical Company Limited Screening method
EP3858838A4 (en) 2018-09-28 2022-06-29 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN117043302A (zh) 2021-03-18 2023-11-10 默克专利有限公司 用于有机电致发光器件的杂芳族化合物
US20250064833A1 (en) 2021-12-13 2025-02-27 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0856001B1 (en) 1995-10-02 2002-08-28 F. Hoffmann-La Roche Ag Pyrimidine derivatives as 5ht2c receptor antagonists
EP0946523A1 (en) * 1996-12-23 1999-10-06 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
KR100607634B1 (ko) * 1998-10-16 2006-08-02 다이닛본 스미토모 세이야꾸 가부시끼가이샤 퀴나졸리논 유도체
JP2005089298A (ja) * 2001-09-18 2005-04-07 Japan Tobacco Inc ナフタレン化合物及びその医薬用途
US20060233843A1 (en) * 2003-02-19 2006-10-19 Conn P J Treatment of psychosis with a muscarinic m1 receptor ectopic activator
EP1888538B1 (en) * 2005-05-04 2009-11-18 F. Hoffmann-Roche AG (3,4-dihydro-quinazolin-2-yl)-(2-aryloxy-ethyl)-amines having an activity on the 5-ht receptor
JP2009542663A (ja) 2006-06-28 2009-12-03 メルク エンド カムパニー インコーポレーテッド ベンジル置換キノロンｍ１受容体ポジティブアロステリックモジュレーター
WO2012047702A1 (en) * 2010-10-04 2012-04-12 Merck Sharp & Dohme Corp. Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators

Also Published As

Publication number Publication date
CA2743562A1 (en) 2010-05-27
US20110224198A1 (en) 2011-09-15
PL2358686T3 (pl) 2013-02-28
MA32898B1 (fr) 2011-12-01
UA100459C2 (en) 2012-12-25
CR20110268A (es) 2011-07-01
EA201170705A1 (ru) 2011-12-30
CN102292323B (zh) 2014-12-24
EP2358686A1 (en) 2011-08-24
IL212573A0 (en) 2011-06-30
HN2011001358A (es) 2014-03-03
HRP20120992T1 (hr) 2012-12-31
HK1154587A1 (en) 2012-04-27
RS52528B (en) 2013-04-30
ECSP11011066A (es) 2011-06-30
DK2358686T3 (da) 2013-01-07
CN102292323A (zh) 2011-12-21
US20140005182A1 (en) 2014-01-02
CO6361928A2 (es) 2012-01-20
ZA201103612B (en) 2012-01-25
US8557832B2 (en) 2013-10-15
SG171769A1 (en) 2011-07-28
EP2358686B1 (en) 2012-09-26
SI2358686T1 (sl) 2013-05-31
CY1113665T1 (el) 2016-06-22
GEP20156348B (en) 2015-08-25
AU2009316578A1 (en) 2011-06-23
GT201100127A (es) 2014-02-10
US20150031713A1 (en) 2015-01-29
CA2743562C (en) 2014-03-18
MY162502A (en) 2017-06-15
MX2011005284A (es) 2011-06-17
JP5102397B2 (ja) 2012-12-19
NZ592961A (en) 2012-09-28
NI201100100A (es) 2011-09-12
US9708273B2 (en) 2017-07-18
DOP2011000135A (es) 2011-07-31
ES2393694T3 (es) 2012-12-27
JP2012509343A (ja) 2012-04-19
US20160229813A1 (en) 2016-08-11
KR101305590B1 (ko) 2013-09-09
IL212573A (en) 2015-01-29
WO2010059773A1 (en) 2010-05-27
TN2011000209A1 (en) 2012-12-17
EA019098B1 (ru) 2014-01-30
US8883810B2 (en) 2014-11-11
KR20110073596A (ko) 2011-06-29
PE20120031A1 (es) 2012-02-05
BRPI0921924A2 (pt) 2015-12-29
PT2358686E (pt) 2012-12-06

Similar Documents

Publication Publication Date Title
SV2011003912A (es) Moduladores de aril metil benzoquinazolinona alostericos positivos del receptor m1
DOP2009000231A (es) Derivados de carboxamida imidazolidina como moduladores de p2x7
UY30411A1 (es) Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones
SV2011004077A (es) Derivados aminobutiricos sustituidos como inhibidores de neprilisina
EA201171197A8 (ru) Замещенные производные азоантрацена, фармацевтические композиции и способы их применения
BR112014032734A2 (pt) derivados de pirrolidina e seu uso como moduladores da série de reação de complemento
CO6470847A2 (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
EA201490477A1 (ru) Фармацевтические составы, содержащие пропиленгликоль-гидрат дапаглифлозина
CO6430422A2 (es) Formulaciones de 4-amino-2-(2,6-dioxopiperidin-1,3-il) isoindolin-1, 3-diona
DOP2006000170A (es) Nuevos derivados de espirocromanona
PE20140099A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
UY30414A1 (es) Metano sulfonatos, propano-1-sulfonatos y ciclopropan sulfonatos sustituidos con [2,3,4,8-tetrahidroimidazo-[1,5-al-pirimidin-8-il]-fenilo, composiciones farmacéuticas conteniéndolos y aplicaciones.
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
CL2011002766A1 (es) Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras.
MX2020011405A (es) Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos.
BR112014001908A2 (pt) derivados aza heterocíclicos substituídos
CY1113759T1 (el) Ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
DOP2013000314A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
CO6460737A2 (es) N-((1r,2s,5r)-5-(tert -butilamino)-2-((s)-3-(7-tert-butilpirazolo[1.5-a][1.3.5]traizin -4-ilamino)-2-oxopirrolidin-1-il)ciclohexil)acetamida, un modulador dual de la actividad del receptor de quimiocinas, formas cristalinas y procesos
BR112015004523A2 (pt) compostos de tetraciclina
UY29823A1 (es) Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones
BRPI0514735B8 (pt) derivados de pirimidino sulfonamida como moduladores do receptor de quimiocina.
DOP2006000287A (es) Derivados de piperidina
AR059864A1 (es) Compuesto de benzamida composicion farmaceutica que lo comprende su uso para preparar un medicamento y procedimientos para su preparacion
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales